Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10851 - 10875 of 11558 in total
G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG. These viruses are specific herpes simplex viruses, or HSVs, generally known as the cause of cold sores. MediGene uses these viruses, however, in a modified and "disarmed" form in order to...
Investigational
Matched Description: … as a therapeutic agent in humans. ... MediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable …
Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated activity in multiple animal models. Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the...
Investigational
Matched Description: … Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 ... Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis …
A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentanecarboxylic acid. A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure.
Experimental
Matched Description: … A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro ... A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic …
"Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the Erythroxylum genus, though this name is also applied to infusions of plants belonging to other genera. The infusion is thought to carry stimulant and aphrodisiac effects, and catuaba made specifically with Trichilia...
Experimental
Matched Description: … "Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _ …
1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC class II-positive tumor cells, which include...
Investigational
Matched Description: … 1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex ... B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a
CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid receptor agonists. In preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal studies suggest that CR665 is a potent analgesic compound. In addition, unlike currently marketed opioids, CR665 does...
Investigational
Matched Description: … Preclinical animal studies suggest that CR665 is a potent analgesic compound. ... CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid …
Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. Melperone has been used for a span of greater than 30 years in the European Union . It has been well established in the treatment of confusion, anxiety, restlessness (particularly in...
Investigational
Matched Description: … Melperone has been used for a span of greater than 30 years in the European Union [L1316]. ... Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316]. …
The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578]. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose . Other features of...
Investigational
Matched Description: … By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one ... Other features of this vaccine include potential activity with oral administration _via_ a swish-and-swallow …
MLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.
Investigational
MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.
Investigational
Matched Description: … MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. …
Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that...
Investigational
Matched Description: … Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which …
GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without affecting normal, healthy nerves. GPI 1485 is being studied in phase 2 clinical trials for the treatment...
Investigational
Matched Description: … GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin …
rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed and is currently under phase I of the clinical trial.
Investigational
Ormeloxifene is a third-generation selective estrogen receptor (ER) modulator. In India, ormeloxifene has been marketed since the 1990s as a non-hormonal, non-steroidal oral contraceptive taken once a week, and it was later introduced for the treatment of dysfunctional uterine bleeding. Similar to other selective estrogen receptor modulators (SERMs), ormeloxifene has...
Experimental
Matched Description: … Ormeloxifene is a third-generation selective estrogen receptor (ER) modulator. ... In India, ormeloxifene has been marketed since the 1990s as a non-hormonal, non-steroidal oral contraceptive ... [A251450,A251460] Ormeloxifene is marketed in India as a racemic mixture of the l- (levormeloxifene) …
Investigational
A methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial lipopolysaccharides. [PubChem]
Experimental
Matched Description: … A methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial …
The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.
Investigational
Matched Description: … The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's …
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Investigational
Matched Description: … MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving …
Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
Investigational
Matched Description: … Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment …
Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Investigational
Matched Description: … Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic …
NS-398 is a COX-2 inhibitor. It was developed as part of the mechanistic study of the cyclooxygenases.
Experimental
Matched Description: … NS-398 is a COX-2 inhibitor. …
PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations In Healthy Volunteers).
Investigational
Matched Description: … PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations …
Pexastimogene devacirepvec is under investigation in clinical trial NCT00429312 (A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma).
Investigational
Matched Description: … Pexastimogene devacirepvec is under investigation in clinical trial NCT00429312 (A Study of Recombinant …
JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).
Investigational
Matched Description: … JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 …
Pecavaptan is under investigation in clinical trial NCT03901729 (A Trial to Study BAY1753011 in Patients With Congestive Heart Failure).
Investigational
Matched Description: … Pecavaptan is under investigation in clinical trial NCT03901729 (A Trial to Study BAY1753011 in Patients …
Displaying drugs 10851 - 10875 of 11558 in total